| Jan. 26, 2015 |
- |
Enlivex Granted EU Orphan Drug Designation for Lead Product ApoCell for Graft-versus-Host Disease
|
|
| Dec. 17, 2014 |
- |
Kahr Medical received government grant sum of 8.2 m shekels approved by the Chief Scientist office.
|
|
| Dec. 12, 2014 |
- |
ProtAb Ltd. Awarded Chinese Patent for Lead Humanized Antibody, Prozumab
|
|
| Nov. 3, 2014 |
- |
Cell Cure Neurosciences Ltd. Receives FDA Authorization to Initiate Phase I/IIa Trial
|
|
| Oct. 21, 2014 |
- |
Written proxy pursuant to Companies Regulations (Voting in Writing and Position Statements) october 2014
|
|
| Sep. 23, 2014 |
- |
Hadasit Bio Invested $460,000 in Protab Company
|
|
| Sep. 18, 2014 |
- |
CellCure reports positive safety for the product
|
|
| Sep. 11, 2014 |
- |
Yigal Erlich- Chairman of the board of directors
|
|
| Aug. 17, 2014 |
- |
Notice from Warrant (Series 4) Holder
|
|
| Aug. 17, 2014 |
- |
RE: Immediate report concerning the general meeting of Company warrant (series 4) holders under Section 350 of the Companies Law
|
|
| Jul. 29, 2014 |
- |
Decision in the Matter of the Extension of the Redemption Period and Reduction of the Price of Redemption of (Series 4) Options part 1
|
|
| Jul. 29, 2014 |
- |
Decision in the Matter of the Extension of the Redemption Period and Reduction of the Price of Redemption of (Series 4) Options part 2
|
|
| Nov. 26, 2012 |
- |
Q3 Report Shows Capital Gain of 7 M NIS
A Series of Events and Funding Including External Investments in Portfolio Companies
|
|
| Jul. 21, 2012 |
- |
Globes interviews CEO Ophir Shahaf
|
|
| Jul. 12, 2012 |
- |
CEO Interviewed by Wall Street Reporter
|
|
| Jun. 19, 2012 |
- |
KAHR Medical raises 10.4 million NIS
|
|
| May. 30, 2012 |
- |
CEO Ophir Shahaf comments on Thrombotech - D-Pharm mereger
|
|
| Apr. 17, 2012 |
- |
Article on Hadasit Bio - Holdings by Leonard Zehr in BioTuesday
|
|
| Apr. 8, 2012 |
- |
The BIRD Foundation Grants BioMarCare and Ariadne $900k
|
|
| Mar. 27, 2012 |
- |
BioMarCare Closes Strategic Investment by Micromedic, a Bio-Light Subsidiary
|
|
| Jan. 19, 2012 |
- |
Hadasit Bio-Holdings' Portfolio Company Thrombotech Raises $1.4M
|
|
| Jan. 10, 2012 |
- |
Thrombotech Raises $1.4 M and Is Expanding Its Phase IIa Trial
|
|
| Jul. 27, 2011 |
- |
About ADRs and how Hadasit Bio-Holdings can benefit from its ADR
|
|
| Jun. 20, 2011 |
- |
An ADR program has been setup (OTCBB:HADSY) for trading in the US
|
|
| May. 25, 2011 |
- |
3 HBL Portfolio Companies Amongst 10 Promising Israeli Biotech Companies on the Verge of a Breakthrough (Calcalist)
|
|
| Apr. 17, 2011 |
- |
Sanofi aventis invests in KAHR Medical
news reports on the deal
|
|
| Mar. 9, 2011 |
- |
Hadasit Bio target is double its share price
Article in Haaretz / TheMarker By Vadim Sviderski
|
|
| Feb. 27, 2011 |
- |
Article on HBL in Hadassah Magazine
Long Road, Short Walk
|
|
| Jan. 23, 2011 |
- |
Article on HBL in Hadassah Magazine
Taking Stock of Hadassah by Wendy Elliman
|
|
| Nov. 9, 2010 |
- |
Attracting the life sciences to Jerusalem
Article published in Isreal 21c By David Shamah
|
|
| Oct. 13, 2010 |
- |
CellCure's 'breakthrough agreement with Big Pharma'
'Perefect Bio Timing' By Patrick Cox
|
|
| Oct. 10, 2010 |
- |
The Cyclic Nature of Biotech Revolutions
A blog by Michael D. West, Ph.D. CEO of BioTime the majority share holder in CellCure
|
|
| Sep. 13, 2010 |
- |
"Investing in Israel for the greater good" Haaretz 13/09/2010
you can be socially responsible and still turn a profit by Elah Alkalay
|
|
| Aug. 31, 2010 |
- |
Report by Globes on TASE Offering
"Hadasit Bio Holdings Raises NIS 11.5m in TASE Offering"
|
|
| Aug. 31, 2010 |
- |
Successful Public Offering
HBL Announces a Successful Public Offering on the TASE - Over 11 Million NIS Raised
|
|
| Aug. 24, 2010 |
- |
Another Major Achievement for Hadasit Bio Holdings (Thrombotech completes phase I)
Thrombotech, a subsidiary of Hadasit Bio Holdings, successfully completed Phase I trial
|
|
| Aug. 19, 2010 |
- |
Q2 2010 report (capital gain of 13 million NIS)
The company reports first substantial capital gain of 13 million NIS
|
|
| Aug. 16, 2010 |
- |
Exclusive Licensing Agreement
BioMarCare Technologies, a subsidiary of Hadasit Bio-Holdings, Has Signed an Exclusive Licensing Agreement with Hadasit for the Commercialization of an Innovative Marker Enabling Early Detection of Cancer
|
|
| Jul. 29, 2010 |
- |
Spotlight on HBL - in "Globes"
"The TASE BioMed Index's Favorite Seeking Partnerships"
|
|
| Jun. 14, 2010 |
- |
3 of HBL's Portfolio Companies Appear in "Israel's Most Promising BioTech Statups" List
ProtAb, KAHR and CellCure included in the list
|
|
| Jun. 13, 2010 |
- |
From Test Tube to Bedside
Israel's only hospital affiliated biopark, located in Jerusalem, helps doctors conduct research
|
|
| Apr. 19, 2010 |
- |
"Swimming Against The Current"
9 Stocks on TASE Post Gains Even When the Market Doesn't
|
|
| Apr. 13, 2010 |
- |
Clal Biotechnology, Pontifax and Hadasit Bio-Holdings to invest $ 4 million in ProtAb, a wholly owned Hadasit Bio-Holdings portfolio company
The company is developing a novel monoclonal antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn’s Disease
|
|
| Mar. 28, 2010 |
- |
Hadassah Breakthrough Increases the Potential to Produce the Large Quantities of Human Embryonic Stem Cells Required For Transplantation
|
|
| Mar. 19, 2010 |
- |
Hadasit - One of "10 Promising Stocks for 2010"
|
|
| Mar. 11, 2010 |
- |
Hadasit Bio Holdings Exploits Its Competitive Advantage
As published in "Globes", March 10th, 2010
|
|
| Mar. 3, 2010 |
- |
Small But Promising Companies
New BioMed Index Attracts Investors in Israel Life Sciences
|
|
| Jan. 24, 2010 |
- |
Tel Aviv Stock Exchange to Launch BioMed Index
38 BioMed Companies on TASE. Index to Allow New Investment Vehicles
|
|
| Dec. 24, 2009 |
- |
KAHR Medical Raises 1.5 M Sheqels from Hadasit Bio-Holdings, Moves Towards Clinical Trial of Immune-system Diseases and Cancer
Invited to Present Preclinical Results at Major Scientific Conferences in Europe and the United States
|
|
| Dec. 6, 2009 |
- |
ProtAb, a Wholly Owned Subsidiary of Hadasit Bio-Holdings, Attracts Funding and Initiates the Manufacturing Process of its Lead Antibody in Preparation for Clinical Trials
|
|
| Nov. 17, 2009 |
- |
Hadasit Bio-Holdings Expands Activity to Diagnostic Markers for Cancer and Sets Up BioMarCare Technologies
The new company has begun a clinical trial of the first marker, for detection of various stages of breast cancer. HBL will inject 1.1 million NIS to bring the trial to completion.
|
|
| Sep. 15, 2009 |
- |
"An Innovation Factory in the Medical Field"
HBL bridges the gap between hospital research and industry
|
|
| Sep. 1, 2009 |
- |
Innovation Powerhouse Applies a New Model For Commercialization
How hadassah is leading Israel’s medical research
|
|
| Jul. 6, 2009 |
- |
Jerusalem Mayor Nir Barkat Visits BioTechnology Park at Hadassah Ein Kerem
Mayor calls the Jerusalem BioPark a central element in the making of Jerusalem
|
|
| Feb. 26, 2009 |
- |
KAHR's Third Generation Biologics Attract Financing
Published in BioWorld Today, Feb. 19th, 2009
|
